ArticleNeurosurgical review2026
Comparative analysis of clinical characteristics and prognostic factors in adult and pediatric patients with H3K27M-mutant diffuse midline glioma.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
H3K27M-mutant diffuse midline glioma (H3K27M-DMG) is a lethal brain tumor predominantly affecting children but increasingly recognized in adults. Emerging evidence suggests potential differences in clinical behavior and survival outcomes between pediatric and adult patients. However, comparative studies remain scarce, and the impact of age on disease progression and treatment response is poorly understood. We conducted a retrospective analysis of 105 patients (51 adults, 54 children) diagnosed with H3K27M-DMG at West China Hospital between January 2016 and August 2021. Clinical data, including demographics, tumor characteristics, treatment modalities, and survival outcomes, were collected. Our analysis revealed that pediatric patients exhibited a shorter median overall survival (OS) than adults (pediatric median OS: 3.65 months [95% CI, 2.73-4.40] vs. adults' median OS: 7.37 months [95%CI, 4.27-13.90]; p = 0.0012). Lower KPS scores and omission of radiotherapy/chemotherapy independently predicting poorer outcomes in both cohorts (all p < 0.01). While elevated Ki67 expression correlated with adverse prognosis in adults (p = 0.011), no molecular markers showed significance in pediatric patients. Best median OS was achieved with trimodality therapy (surgery, radiation, and chemotherapy) across all age groups. This study provides a comprehensive comparative analysis of clinicopathological characteristics and survival outcomes between pediatric and adult H3K27M-DMG patients. Through multivariate analysis, we identified key independent prognostic factors. Low preoperative Karnofsky Performance Scale (KPS) score was an independent risk factor in the pediatric cohort, whereas both low preoperative KPS score and omission of radiotherapy were independent risk factors in the adult cohort. This study highlights distinct age-specific risk profiles in H3K27M-DMG, emphasizing that prognostic stratification and treatment strategies should be tailored accordingly for pediatric versus adult patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.